OpGen « Terug naar discussie overzicht

Curetis-OpGen - 2020: wordt het nog wat..?

2.575 Posts, Pagina: « 1 2 3 4 5 6 ... 54 55 56 57 58 59 60 61 62 63 64 ... 125 126 127 128 129 » | Laatste
whoiam
0
quote:

DeZwarteRidder schreef op 17 maart 2020 16:36:

[...]

OpGen gaat op 30 maart toestemming geven en de rest is een formaliteit.
zit jij dan in opgen?
PGV
0
[verwijderd]
0
quote:

Jemoetwat schreef op 17 maart 2020 16:54:

Gokje gewaagd. 1000 stukjes gekocht
Tsja je moet wat in deze tijden....
Tootje24
0
quote:

Beginnende schreef op 17 maart 2020 16:52:

Poil waar blijf je met je positieve inspiratie ????????
Mee eens!
Ronduit
0
Even bijkomen van een hectische (ochtend) dag. Morgen weer nieuwe, ronde nieuwe kansen.
Börs
0
quote:

maurice 1971 schreef op 17 maart 2020 16:59:

Nog wat ingeslagen
AYTU, bedoel je hopelijk. :-)
DeZwarteRidder
0
quote:

Eis2020 schreef op 17 maart 2020 17:01:

Voor diegene die AYTU volgden news out!
Updated FDA Policy Likely Enables Near-Term Availability of COVID-19 Test in the U.S.

ENGLEWOOD, CO / ACCESSWIRE / March 17, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs announced today that the company intends to expedite the U.S. launch of its recently licensed COVID-19 IgG/IgM Point-of-Care Rapid Test in light of yesterday's updated FDA policy on coronavirus diagnostic testing.

On March 16, 2020 the FDA announced, "as part of our ongoing and aggressive commitment to address the coronavirus outbreak, the FDA updated a policy originally issued on Feb. 29 on diagnostic testing for coronavirus (COVID-19) in order to achieve more rapid testing capacity in the U.S. We believe the unprecedented policy set forth in today's updated guidance, which addresses laboratories and commercial manufacturers, will help address these urgent public health concerns by helping to expand the number and variety of diagnostic tests..." Further, the agency made recommendations specifically for test developers stating that "the FDA does not intend to object to the distribution and use of serology tests to identify antibodies to SARS-CoV-2 where the test has been validated" and other labeling conditions are satisfied.

Josh Disbrow, Chief Executive Officer of Aytu BioScience, commented, "While we are still working with FDA on making the COVID-19 Rapid Test available, we believe that this updated policy may enable near-term availability of our recently-licensed point-of-care test. During this public health emergency, we are working tirelessly to satisfy all requirements in order to make the test available to the professional medical community as soon as possible." Disbrow also commented that, "We have already gotten confirmation from the manufacturer that our initial supply is being shipped and is expected to arrive in the U.S. very soon."

The company will continue to provide updates about the near-term availability of the COVID-19 test.
maurice 1971
0
Börs
0
[verwijderd]
0
quote:

Eis2020 schreef op 17 maart 2020 17:01:

Voor diegene die AYTU volgden news out!

www.finanznachrichten.de/nachrichten-...
Ik ben snel ingesprongen op de AYTU trein, coupé 1,70 Volle vaart zouk zo zeggen! Who needs Holland Casino? ;-)
[verwijderd]
0
Instappen kan nog, nieuws lijkt nog niet algemeen uit en shorts houden 1,80 nog vast maar gaat zo niet lang meer duren.
2.575 Posts, Pagina: « 1 2 3 4 5 6 ... 54 55 56 57 58 59 60 61 62 63 64 ... 125 126 127 128 129 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd 26 apr 2024 22:00
Koers 0,515
Verschil -0,017 (-3,21%)
Hoog 0,540
Laag 0,480
Volume 437.254
Volume gemiddeld 1.690.387
Volume gisteren 164.213

EU stocks, real time, by Cboe Europe Ltd.; Other, Euronext & US stocks by NYSE & Cboe BZX Exchange, 15 min. delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by: Infront